Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 24, 2024
Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practiceOfer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, et al.
Journal of the American College of Cardiology|April 4, 2006
Effects of normal aging on left ventricular lusitropic, inotropic, and chronotropic responses to dobutaminePaul S Hees, Jerome L Fleg, Zulfiqar A Mirza, et al.
Journal of Psychiatric Research|November 10, 2020
Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophreniaKyle Daniell, Julia Kim, Yusuke Iwata, et al.
The International Journal of Neuropsychopharmacology|May 8, 2009
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidolSteven G Potkin, Peter J Weiden, Antony D Loebel, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 16, 2018
Associations of the serotonin transporter promoter polymorphism (5-HTTLPR) with bipolar disorder and treatment response: A systematic review and meta-analysisShitao Rao, Xinyu Han, Mai Shi, et al.
Schizophrenia Research|November 26, 2018
Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environmentIshraq Siddiqui, Sarah Saperia, Gagan Fervaha, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 7, 2008
The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET studyAriel Graff-Guerrero, Romina Mizrahi, Ofer Agid, et al.
NPJ Schizophrenia|January 9, 2020
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future researchSteven G Potkin, John M Kane, Christoph U Correll, et al.
Comprehensive Psychiatry|September 8, 2020
Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophreniaBrian J Miller, Andrei Pikalov, Cynthia O Siu, et al.
Pageof 13